Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A.

Nyxoah develops sleep therapy solutions for patients with moderate to severe Obstructive Sleep Apnea (OSA). Their product, Genio, is a treatment for obstructive sleep apnea designed for people who cannot tolerate, have failed or refused CPAP therapy.

Nyxoah

Nyxoah is a pioneering medical device company developing a breakthrough therapeutic solution for the treatment of Obstructive Sleep Apnea (OSA). 

Our mission is to become a world leading company by offering unique patient-centric neuromodulation solutions, developed by passionate and exceptionally driven people

Nyxoah's therapy Genio® offers:
    - Unparalleled clinical efficacy
    - Increased patient comfort, therapy compliance and quality of life
    - Minimally invasive approach, thus streamlining patient flow and reducing surgery related risks
    - Positive health economics outcomes by reducing the burden of OSA and its comorbidities

Cochlear

ResMed

European Investment Bank

Viralety Ventures

Gilde Healthcare

S.R.I.W.

Mark your calendars! 📅 

Nyxoah is a proud platinum sponsor at the iBEDSSMA symposium on September 21st, celebrating their 10th anniversary! 

Be part of this exciting event in Antwerp, where experts will share insights on the latest developments in sleep technology and multidisciplinary treatment. 

Make sure you don’t miss out. Check the link for the program and registration. https://lnkd.in/gzQiTEvb 

Looking forward to seeing you in Antwerp! 

#Sleep #OSA #iBEDSSMA #Genio #Precisionmedicine #Sleeptechnology #Sleephealth #ENT #HGNS #neurostimulation

Nyxoah appoints Scott Holstine as Chief Commercial Officer. We are honoured to welcome such an experienced sales executive to lead the commercial operations of Nyxoah enabling a successful U.S. launch of #Genio.

#OSA #RestfulNights #MakeSleepSimpleAgain 


https://lnkd.in/eWvW9DBM

🚨 New Study Alert! 🚨 

The latest German systematic literature review on Hypoglossal Nerve Stimulation (HGNS) for Obstructive Sleep Apnea (OSA) is published – and it's an interesting read!

The review analyzed 33 publications, consistently confirming HGNS as an effective and safe treatment for OSA patients who have not found success with CPAP therapy. 

The results across various studies were remarkably consistent, highlighting HGNS's potential to fill the treatment gap in OSA management.

HGNS stands out as a fully reversible neurostimulation procedure that can be customized to individual patient needs. This adaptability is crucial in optimizing therapy, offering options like bilateral or battery-free stimulation to enhance comfort and ease of use.

Read the full article here:  https://lnkd.in/g_k5GxWV  

#sleepresearch #HGNS #Genio #sleepapneatreatment #OSA #sleepapnea #Nyxoah #patientcentriccare #sleephealth #neurostimulation

EIB President Mrs. Nadia Calviño highlights the #1week1minute of the European Investment Bank (EIB). This bank invests in the things that matter and shares a passion for shaping a better future for the European Union and beyond. 
Nyxoah is featured in the video below! 🎥 

https://lnkd.in/enw-5ebs

#EUinvest #Genio #Nyxoah #MedTech #OSA #Sleepapnea

Key Opinion Leader, Professor Dr. Olivier M Vanderveken MD, PhD at Antwerp University Hospital offers his expert perspective on Nyxoah's recent funding and its implications for OSA patients and Hypoglossal Nerve Stimulation (HGNS).  

He highlights the expected advancements in clinical trials and technology and the subsequent enhancements in patient care.

https://lnkd.in/eG3h6tW9

Thank you, Prof. Vanderveken for sharing your expertise in this video!

#grateful #patientcentriccare #OSA #Genio #Nyxoah #otolaryngology #precisionmedicine #obstructivesleepapnea #sleepmedicine #surgery #ent #neurostimulation

🎥 Discover key insights from Nyxoah CFO Mr. Loïc Moreau on the €37.5 Million loan facility agreement from the European Investment Bank (EIB) in this video.

https://lnkd.in/e7cHsvmQ 

The funding will accelerate the commercialization of Genio in the U.S. and Europe, while enhancing production capacity and driving ongoing innovation. 

Stay tuned for updates on our journey!

#Nyxoah #Genio #InvestEU #Innovation #OSA #MedTech #makesleepsimpleagain

Excited and grateful for the support of the European Investment Bank (EIB)  in our Genio technology!  

Thank you for your trust. We look forward to a continued strong collaboration between Nyxoah and the European Investment Bank (EIB) teams.
#Innovation #Technology #Collaboration #Nyxoah #Genio #InvestEU #OSA #MedTech

🌟 Exciting News at Nyxoah!! 🌟

We are thrilled to announce that Nyxoah has secured a €37.5 Million Loan Facility Agreement from the European Investment Bank (EIB). 
Mr. Y Zhang Head of Division - Equity and Growth Capital - Industry 4.0 & Life Sciences from EIB and our CEO Mr. Olivier Taelman, officially signed the agreement today!

This significant funding will enable us to accelerate our research and development efforts, scale-up manufacturing and expand our market reach. It’s a strong endorsement of our mission to enhance the lives of those suffering from obstructive sleep apnea through cutting-edge technology. 

We extend our gratitude to the EIB for their confidence in our vision and commitment to improving sleep health worldwide and make sleep simple again. 

https://lnkd.in/ekg4bQ-F

Stay tuned for more updates as we continue our journey towards transforming sleep apnea treatment! 

#InvestEU #EIB #Nyxoah #Genio #OSA #CPAPalternative #innovation #makesleepsimpleagain

We were delighted to join the panel discussion from HLTH Europe during their recent event.

Our CFO, Loïc Moreau shared his strategic insights and perspective on MedTech paths in US vs. Europe and how #Nyxoah is getting ready to commercialise our #Genio system in the US in a few months.

We are proud to announce that Nyxoah has successfully completed the first Genio® implant in Colorado and the furthest West in the U.S., under the ACCCESS study! 🌟 
Congratulations to Dr. Nicholas Beckmann, Monica Davis and team on this achievement at COLORADO ENT & ALLERGY St. Francis Medical Center in Colorado Springs. We extend our gratitude to Colin Huntley, MD from Thomas Jefferson University, Philadelphia, PA, for his expert guidance.
Together, we are advancing medical research and enhancing patient-centered OSA care! 
#Genio #ACCCESSstudy #OSA #ENT #Nyxoah

NASDAQ:NYXH